{
    "id": 3205,
    "fullName": "ESR1 D538G",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ESR1 (ER alpha) D538G lies within the ligand-binding domain of the Esr1 (Er alpha) protein (UniProt.org). D538G results in activation of the Esr1 (Er alpha) protein and downstream signaling (PMID: 24185510, PMID: 24185512, PMID: 29438694), estrogen independent transcription of target genes, as well as regulation of additional genes, and enhanced migration (PMID: 31362937), and increases proliferation and cell viability as compared to wild-type Esr1 (PMID: 29533785).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 1930,
                    "pubMedId": 24185510,
                    "title": "Activating ESR1 mutations in hormone-resistant metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24185510"
                },
                {
                    "id": 11217,
                    "pubMedId": 29438694,
                    "title": "Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29438694"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                },
                {
                    "id": 1929,
                    "pubMedId": 24185512,
                    "title": "ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24185512"
                },
                {
                    "id": 15937,
                    "pubMedId": 31362937,
                    "title": "Estrogen-independent molecular actions of mutant estrogen receptor 1 in endometrial cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31362937"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2099,
        "geneSymbol": "ESR1",
        "terms": [
            "ESR1",
            "ER",
            "Era",
            "ESR",
            "ESRA",
            "ESTRR",
            "NR3A1"
        ]
    },
    "variant": "D538G",
    "createDate": "02/18/2015",
    "updateDate": "08/08/2019",
    "referenceTranscriptCoordinates": {
        "id": 111970,
        "transcript": "NM_000125",
        "gDna": "chr6:g.152098791A>G",
        "cDna": "c.1613A>G",
        "protein": "p.D538G",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1855,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human breast cell lines expressing ESR1 D538G demonstrated decreased response when treated with Nolvadex (tamoxifen) (PMID: 24185512).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 1929,
                    "pubMedId": 24185512,
                    "title": "ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24185512"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21228,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Elacestrant (RAD1901) treatment resulted in estrogen receptor degradation and inhibition of ER signaling, led to inhibition of growth of both CDK4/6 inhibitor-sensitive and CDK4/6 inhibitor-resistant breast cancer cell lines harboring ESR1 D538G in culture, and tumor growth inhibition in patient-derived xenograft models (PMID: 31852484).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 5890,
                "therapyName": "Elacestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3647,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bazedoxifene inhibited proliferation of human breast cancer cells expressing ESR1 D538G, however, with decreased response compared to wild-type ESR1 expressing cells (PMID: 25991817).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 2737,
                "therapyName": "Bazedoxifene",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21223,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Verzenio (abemaciclib) inhibited cell cycle progression and proliferation of long-term estrogen deprived` breast cancer cells harboring ESR1 D538G in culture (PMID: 31852484).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16412,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, H3B-5942 inhibited ESR1 (ER alpha) target gene expression and proliferation of an ESR1 (ER alpha)-positive breast cancer cell line expressing ESR1 D538G in culture (PMID: 29991605).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 8021,
                "therapyName": "H3B-5942",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14484,
                    "pubMedId": 29991605,
                    "title": "Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ER\u03b1WT and ER\u03b1MUT Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29991605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10231,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Faslodex (fulvestrant) inhibited ESR1 activity and growth of breast cancer cells expressing ESR1 D538G, with ESR1 D538G-expressing cells demonstrating reduced sensitivity compared to cells expressing wild-type ESR1, and inhibited tumor growth in xenograft models (PMID: 27986707).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8160,
                    "pubMedId": 27986707,
                    "title": "Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27986707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3644,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Faslodex (fulvestrant) inhibited cell proliferation of human breast cancer cells expressing ESR1 D538G, however, exhibited a decreased response when compared to ESR1 wild-type expressing cells in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6624,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human breast cell lines expressing ESR1 D538G demonstrated decreased sensitivity to inhibition by Falsodex (fulvestrant) in culture (PMID: 24185512).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1929,
                    "pubMedId": 24185512,
                    "title": "ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24185512"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3650,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human breast cancer cell lines expressing ESR1 D538G were less sensitive than ESR1 wild-type expressing cells to inhibition by pipendoxifene in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 3207,
                "therapyName": "pipendoxifene",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21222,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kisqali (ribociclib) inhibited cell cycle progression and proliferation of long-term estrogen deprived` breast cancer cells harboring ESR1 D538G in culture (PMID: 31852484).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21221,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited cell cycle progression and proliferation of long-term estrogen deprived` breast cancer cells harboring ESR1 D538G in culture (PMID: 31852484).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18448,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARV-471 treatment inhibited growth of a breast cancer cell line expressing ESR1 D538G in culture (Cancer Res 2019;79(4 Suppl):Abstract nr P5-04-18).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 8716,
                "therapyName": "ARV-471",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16183,
                    "pubMedId": null,
                    "title": "ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer",
                    "url": "https://cancerres.aacrjournals.org/content/79/4_Supplement/P5-04-18"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11903,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G1T48 treatment reduced Esr1 protein expression, resulting in growth inhibition in breast cancer cells overexpressing ESR1 D538G in culture (Cancer Res 2017;77(13 Suppl):Abstract nr 5641).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 6206,
                "therapyName": "G1T48",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9895,
                    "pubMedId": null,
                    "title": "Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5641.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9022,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vistusertib (AZD2014) resulted in anti-tumor activity in a patient derived primary explant xenograft (PDX) model of ER positive breast cancer harboring ESR1 D538G (PMID: 26358751).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 991,
                "therapyName": "Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6854,
                    "pubMedId": 26358751,
                    "title": "AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26358751"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10212,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC-0810 inhibited growth of breast cancer cells expressing ESR1 D538G in culture, and inhibited tumor growth in xenograft models (PMID: 27986707).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 2150,
                "therapyName": "GDC-0810",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8160,
                    "pubMedId": 27986707,
                    "title": "Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27986707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16429,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and H3B-5942 demonstrated synergy in an ESR1 (ER alpha)-positive breast cancer cell line expressing ESR1 D538G, resulting in decreased proliferation in culture (PMID: 29991605).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 8022,
                "therapyName": "H3B-5942 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14484,
                    "pubMedId": 29991605,
                    "title": "Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ER\u03b1WT and ER\u03b1MUT Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29991605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4546,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III trial, estrogen-receptor (ER)-positive breast cancer patients harboring ESR1 D538G demonstrated improved progression-free survival when treated with a combination of Aromasin (exemestane) plus Afinitor (everolimus) versus Aromasin (exemestane) alone (5.8 vs 2.7 months) (PMID: 26681738).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 1966,
                "therapyName": "Everolimus + Exemestane",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4594,
                    "pubMedId": 26681738,
                    "title": "ESR1 Mutations Prevalent in Some Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26681738"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6928,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD9496 inhibited tumor growth in patient-derived xenograft models of breast cancer harboring ESR1 D538G (PMID: 27020862).",
            "molecularProfile": {
                "id": 3029,
                "profileName": "ESR1 D538G"
            },
            "therapy": {
                "id": 2997,
                "therapyName": "AZD9496",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5956,
                    "pubMedId": 27020862,
                    "title": "AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020862"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3659,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human breast cancer cell lines expressing ESR1 Y537N ESR1 D538G were less sensitive than ESR1 wild-type expressing cells to inhibition by pipendoxifene in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 14081,
                "profileName": "ESR1 Y537N ESR1 D538G"
            },
            "therapy": {
                "id": 3207,
                "therapyName": "pipendoxifene",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3660,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human breast cancer cell lines expressing ESR1 Y537N ESR1 D538G were less sensitive than ESR1 wild-type expressing cells to inhibition by Faslodex (fulvestrant) in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 14081,
                "profileName": "ESR1 Y537N ESR1 D538G"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3661,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human breast cancer cell lines expressing ESR1 Y537N ESR1 D538G were less sensitive than ESR1 wild-type expressing cells to inhibition by bazedoxifene in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 14081,
                "profileName": "ESR1 Y537N ESR1 D538G"
            },
            "therapy": {
                "id": 2737,
                "therapyName": "Bazedoxifene",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3656,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) had no effect on tumor growth in patient derived breast cancer xenografts harboring ESR1 D538G and decreased RB1 expression (PMID: 25991817).",
            "molecularProfile": {
                "id": 15729,
                "profileName": "ESR1 D538G RB1 dec exp"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8046,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, the treatment addition of Afinitor (everolimus) to Aromasin (exemestane) in breast cancer patients co-harboring ESR1 Y537S and ESR1 D538G did not appear to provide a significant benefit to progression free survival (PMID: 27532364).",
            "molecularProfile": {
                "id": 26140,
                "profileName": "ESR1 Y537S ESR1 D538G"
            },
            "therapy": {
                "id": 1966,
                "therapyName": "Everolimus + Exemestane",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6541,
                    "pubMedId": 27532364,
                    "title": "Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27532364"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9706,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, an estrogen-receptor positive breast cancer patient harboring ESR1 D538G and a PIK3CA mutation demonstrated a clinical benefit when treated with the combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994).",
            "molecularProfile": {
                "id": 26994,
                "profileName": "ESR1 D538G PIK3CA mut"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7484,
                    "pubMedId": 27126994,
                    "title": "A Phase Ib Study of Alpelisib (BYL719), a PI3K\u03b1-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27126994"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10236,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD9496 reduced tumor growth in a breast cancer patient-derived xenograft (PDX) model harboring ESR1 D538G, which also harbored PIK3CA N345K, ARID1A E1776*, and ARID1A S705fs (PMID: 27986707).",
            "molecularProfile": {
                "id": 27322,
                "profileName": "ARID1A S705fs ARID1A E1776* ESR1 D538G PIK3CA N345K"
            },
            "therapy": {
                "id": 2997,
                "therapyName": "AZD9496",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8160,
                    "pubMedId": 27986707,
                    "title": "Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27986707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3029,
            "profileName": "ESR1 D538G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14081,
            "profileName": "ESR1 Y537N ESR1 D538G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 15729,
            "profileName": "ESR1 D538G RB1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26140,
            "profileName": "ESR1 Y537S ESR1 D538G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26994,
            "profileName": "ESR1 D538G PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27322,
            "profileName": "ARID1A S705fs ARID1A E1776* ESR1 D538G PIK3CA N345K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 111961,
            "transcript": "XM_011535543",
            "gDna": "chr6:g.152098791A>G",
            "cDna": "c.1613A>G",
            "protein": "p.D538G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111966,
            "transcript": "NM_001122741",
            "gDna": "chr6:g.152098791A>G",
            "cDna": "c.1613A>G",
            "protein": "p.D538G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111967,
            "transcript": "XM_017010381",
            "gDna": "chr6:g.152098791A>G",
            "cDna": "c.1613A>G",
            "protein": "p.D538G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111968,
            "transcript": "XM_011535544",
            "gDna": "chr6:g.152098791A>G",
            "cDna": "c.1613A>G",
            "protein": "p.D538G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111965,
            "transcript": "XM_011535545",
            "gDna": "chr6:g.152098791A>G",
            "cDna": "c.1613A>G",
            "protein": "p.D538G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111960,
            "transcript": "XM_017010380",
            "gDna": "chr6:g.152098791A>G",
            "cDna": "c.1613A>G",
            "protein": "p.D538G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111958,
            "transcript": "XM_017010377",
            "gDna": "chr6:g.152098791A>G",
            "cDna": "c.1613A>G",
            "protein": "p.D538G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111964,
            "transcript": "XM_017010379",
            "gDna": "chr6:g.152098791A>G",
            "cDna": "c.1613A>G",
            "protein": "p.D538G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111969,
            "transcript": "NM_001122740",
            "gDna": "chr6:g.152098791A>G",
            "cDna": "c.1613A>G",
            "protein": "p.D538G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111963,
            "transcript": "XM_017010378",
            "gDna": "chr6:g.152098791A>G",
            "cDna": "c.1613A>G",
            "protein": "p.D538G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111959,
            "transcript": "XM_017010376",
            "gDna": "chr6:g.152098791A>G",
            "cDna": "c.1613A>G",
            "protein": "p.D538G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111962,
            "transcript": "NM_001122742",
            "gDna": "chr6:g.152098791A>G",
            "cDna": "c.1613A>G",
            "protein": "p.D538G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111970,
            "transcript": "NM_000125",
            "gDna": "chr6:g.152098791A>G",
            "cDna": "c.1613A>G",
            "protein": "p.D538G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}